"If you want land we will give you. If you want to own everything 100%, we don't mind, just produce from the African continent," he told the firms.
Global pharmaceutical firms should license production of COVID-19 vaccines in Africa rather than just do piecemeal contract deals, Masiyiwa said while speaking a day after Pfizer and BioNTech announced a "fill and finish" deal with South Africa's Biovac Institute under which it will carry out the final stages of vaccine manufacturing where the product is processed and put into vials.
Pfizer and BioNTech will handle drug substance production at their facilities in Europe. Medicines Sans Frontiers (MSF) has called the arrangement "restrictive" and said much more is needed to support vaccine independence in Africa.
"We want to make clear to all suppliers... if you want a long-term future with us now, you produce from Africa," Masiyiwa said.
Africa, which is battling a third wave of infections, has administered just 60 million vaccine doses in a population of 1.3 billion due to restrictions on shipments from vaccine producing nations like India.
Many African nations rely on global vaccine sharing scheme COVAX or donations from countries like China and India.